natgillin/translations-raw huggingface dataset:
Farmakokinetik i specielle populationr:
Pharmacokinetics in specialpopulations:
farmakokinetik ikke ændret af
not altered by rifabutin.
Farmakokinetik observeret hos patienter med reumatoid artritis var tilsvarende den, som blev set hos raske personer.
Pharmacokinetics observed in patients with rheumatoid arthritis were consistent with those seen in healthy subjects.
Farmakokinetik og
The pharmacokinetics and dosing
Farmakokinetik og metabolisering
Pharmacokinetics and Drug Metabolism
Farmakokinetik under graviditet
Pharmacokinetics in pregnancy
farmakokinetik).
enhancement).
Farmakokinetik, sikkerhed, tolerabilitet og virkning af PREZISTA/ritonavir to gange dagligt i kombination med andre antiretrovirale lægemidler hos 21 ART-erfarne hiv-1 smittede pædiatriske patienter i alderen 3 til < 6 år med en legemsvægt på 10 kg til < 20 kg blev evalueret i et åbent fase II- studie, ARIEL.
The pharmacokinetics, safety, tolerability and efficacy of PREZISTA/ritonavir twice daily in combination with other antiretroviral agents in 21 ART-experienced HIV-1 infected paediatric patients aged 3 to < 6 years and weighing 10 kg to < 20 kg was evaluated in an open-label, Phase II trial, ARIEL.
Farmakokinetik, sikkerhed, tolerabilitet og virkning af PREZISTA/ritonavir to gange dagligt i kombination med andre antiretrovirale lægemidler hos 21 ART-erfarne hiv-1-smittede pædiatriske patienter i alderen 3 til < 6 år med en legemsvægt på 10 kg til < 20 kg blev evalueret i et åbent fase II- studie, ARIEL.
The pharmacokinetics, safety, tolerability and efficacy of PREZISTA/ritonavir twice daily in combination with other antiretroviral agents in 21 ART-experienced HIV-1 infected paediatric patients aged 3 to < 6 years and weighing 10 kg to < 20 kg was evaluated in an open-label, Phase II trial, ARIEL.
Farmakokinetik, sikkerhed, tolerabilitet og virkning af rilpivirin 25 mg én gang dagligt i kombination med et investigator-valgt BR med to NRTI’er blev evalueret i forsøget TMC278-C213, et enkeltarmet, åbent fase 2-forsøg med antiretroviral-naive hiv 1-inficerede unge forsøgspersoner, der vejede mindst 32 kg.
The pharmacokinetics, safety, tolerability and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, was evaluated in trial TMC278-C213, a single-arm, open-label Phase 2 trial in antiretroviral treatment-naïve HIV-1 infected adolescent subjects weighing at least 32 kg.
Farmakokinetik, virkning og sikkerhed af Envarsus og tacrolimus-kapsler med øjeblikkelig udløsning, begge i kombination med kortikosteroider, blev sammenlignet hos 117 levertransplanterede patienter, hvoraf 88 blev behandlet med Envarsus.
The pharmacokinetics, efficacy and safety of Envarsus and tacrolimus immediate-release capsules , both in combination with corticosteroids was compared in 117 liver transplant recipients, of whom 88 received treatment with Envarsus.
Farmakokinetiken for deferasirox er ikke undersøgt for ældre patienter (65 år eller derover).
The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or older).
Farmakokinetikken af abacavir er ikke undersøgt hos patienter over 65 år.
The pharmacokinetics of abacavir has not been studied in patients over 65 years of age.
Farmakokinetikken af Aripiprazole og dehydro Aripiprazole hos pædiatriske patienter i alderen 10-17 år, svarede til den hos voksne, efter der er taget højde for forskellen i kropsvægt.
The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.
Farmakokinetikken af autoinduktionen karakteriseres ved en tilnærmelsesvis 1,5-2 gange stigning i den åbenbare perorale clearance af nevirapin når en behandling fortsættes fra en enkeltdosis til 2-4 ugers behandling med 200-400 mg dagligt.
The pharmacokinetics of autoinduction is characterised by an approximately 1.5 to 2 fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg/day.
Farmakokinetikken af Caelyx bestemt i 11 patienter med ovariecarcinom var lig farmakokinetikken bestemt i en større population på 120 patienter med forskellige cancerformer.
The pharmacokinetics of Caelyx determined in 11 patients with ovarian carcinoma were similar to the pharmacokinetics determined in the larger population of 120 patients with various cancers.
Farmakokinetikken af darunavir i kombination med ritonavir taget en gang dagligt hos
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in
Farmakokinetikken af dexmedetomidin i plasma er ens hos patienter på intensivafelinger efter en infusion >24 timer.
Plasma pharmacokinetics of dexmedetomidine is similar in the ICU population following infusion >24 h.
Farmakokinetikken af dextromethorphan/kinidin hos pædiatriske patienter er ikke undersøgt (se pkt.
The pharmacokinetics of dextromethorphan/quinidine in paediatric patients has not been studied (see section 5.1).
Farmakokinetikken af disse lægemidler, som udskilles via det samme renale system, herunder transportproteinerne (hOAT) 1 og 3 eller MRP 4, kan derfor forandre sig, hvis de indgives samtidig.
Consequently, the pharmacokinetics of these medicinal products, which are secreted by the same renal pathway including transport proteins hOAT 1 and 3 or MRP 4, might be modified if they are co-administered.
Farmakokinetikken af dolutegravir hos 10 ART-erfarne hiv-1-inficerede unge (fra 12 år til < 18 år) viste, at en dosering på 50 mg Tivicay oralt en gang daglig resulterede i en eksponering for dolutegravir, der var sammenlignelig med den eksponering, der blev observeret hos voksne, som fik 50 mg Tivicay oralt en gang daglig.
The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to <18 years of age) showed that Tivicay 50 mg once daily oral dosage resulted in dolutegravir exposure comparable to that observed in adults who received Tivicay 50 mg orally once daily.
Farmakokinetikken af dulaglutid blev vurderet i et klinisk farmakologistudie, og den var generelt ensartet hos raske frivillige og hos patienter med let til svær nyreinsufficiens (CrCl < 30 ml/min.), inklusive nyresygdom i slutstadiet (dialysekrævende).
The pharmacokinetics of dulaglutide were evaluated in a clinical pharmacology study and were generally similar between healthy subjects and patients with mild to severe renal impairment (CrCl < 30 ml/min), including end stage renal disease (requiring dialysis).
Farmakokinetikken af efavirenz, emtricitabin og tenofovirdisoproxilfumarat efter samtidig administration af de enkelte lægemiddelformer eller som Atripla er ikke blevet undersøgt hos hiv-inficerede patienter med nedsat nyrefunktion.
The pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil fumarate after co-administration of the separate pharmaceutical forms or as Atripla have not been studied in HIV infected patients with renal impairment.
Farmakokinetikken af florbetaben (18F) hos patienter med nyre- eller leverinsufficiens er ikke undersøgt.
The pharmacokinetics of florbetaben (18F) in patients with renal or hepatic impairment has not been characterised.
Farmakokinetikken af fosamprenavir i kombination med ritonavir er ikke blevet undersøgt hos patien- ter over 65 år.
The pharmacokinetics of fosamprenavir in combination with ritonavir has not been studied in patients over 65 years of age.
Farmakokinetikken af guanfacin er tilsvarende for børn (i alderen 6-12 år) og unge (i alderen 13-17 år) hos ADHD-patienter og raske voksne frivillige.
The pharmacokinetics of guanfacine is similar in children (aged 6 to 12) and adolescent (aged 13 to 17) ADHD patients, and healthy adult volunteers.
Farmakokinetikken af indinavir synes ikke at påvirkes af race.
Pharmacokinetics of indinavir do not appear to be affected by race.
Farmakokinetikken af insulin lispro afspejler hurtig absorption og opnåelse af maksimal plasma- koncentration 30 - 70 minutter efter subkutan injektion.
The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels 30 to 70 minutes following subcutaneous injection.
Farmakokinetikken af insulin lispro afspejler hurtig absorption og opnåelse af maksimal plasmakoncentration 30 - 70 minutter efter subkutan injektion.
The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels 30 to 70 minutes following subcutaneous injection.
Farmakokinetikken af intravenøs mepolizumab blev evalueret ved en farmakokinetisk populationsanalyse i et pædiatrisk studie hos personer i alderen 2-17 år med eosinofil øsofagitis.
Intravenous mepolizumab pharmacokinetics was evaluated by population pharmacokinetic analysis in a paediatric study conducted in subjects aged 2–17 years old with eosinophilic esophagitis.
Farmakokinetikken af IntronA blev undersøgt hos raske forsøgspersoner efter enkeltdoser på 5 millioner IE/m2 og 10 millioner IE indgivet subkutant, ved doser på 5 millioner IE/m2 indgivet intramuskulært og som en 30 minutters intravenøs infusion.
The pharmacokinetics of IntronA were studied in healthy volunteers following single 5 million IU/m2 and 10 million IU doses administered subcutaneously, at 5 million IU/m2 administered intramuscularly and as a 30-minute intravenous infusion.
Farmakokinetikken af Kaletra
The pharmacokinetics of
Farmakokinetikken af liraglutid blev vurderet hos forsøgspersoner med varierende grader af nedsat leverfunktion i et enkeltdosisstudie.
The pharmacokinetics of liraglutide was evaluated in subjects with varying degrees of hepatic impairment in a single-dose trial.
Farmakokinetikken af liraglutid blev vurderet hos patienter med varierende grader af nedsat leverfunktion i et enkeltdosisstudie.
The pharmacokinetics of liraglutide was evaluated in patients with varying degree of hepatic impairment in a single­dose trial.
Farmakokinetikken af naloxegol i den pædiatriske population er ikke blevet undersøgt.
The pharmacokinetics of naloxegol in the paediatric population has not been studied.
Farmakokinetikken af NovoMix 30 har ikke været undersøgt hos børn og unge.
The pharmacokinetics of NovoMix 30 have not been investigated in children or adolescents.
Farmakokinetikken af oral aripiprazol og dehydroaripiprazol hos pædiatriske patienter i alderen 10- 17 år, svarede til den hos voksne,, efter der er taget højde for forskellen i kropsvægt.
The pharmacokinetics of oral aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.
Farmakokinetikken af palonosetron eller netupitant er ikke blevet undersøgt hos personer med nyresygdom i slutstadiet med behov for hæmodialyse, og der foreligger ingen data om Akynzeos virkning og sikkerhed hos disse patienter.
The pharmacokinetics of palonosetron or netupitant has not been studied in subjects with end-stage renal disease requiring hemodialysis and no data on the effectiveness or safety of Akynzeo in these patients are available.
Farmakokinetikken af pitolisant hos patienter i alderen fra 68 til 80 år er sammenlignelig med farmakokinetikken hos yngre patienter (i aldren fra 18 til 45 år).
In 68 to 80 years old patients the pharmacokinetics of pitolisant is not different compared to younger patients (18 to 45 years of age).
Farmakokinetikken af pixantron er påvist at være lineær inden for et bredt dosisområde fra 3 mg/m2 til 105 mg/m2.
Pharmacokinetics of pixantrone proved to be linear in a broad range of doses, from 3 mg/m2 to 105 mg/m2.
Farmakokinetikken af rilpivirin og tenofovirdisoproxilfumarat hos børn og teenagere er i gang med at blive undersøgt.
The pharmacokinetics of rilpivirine and tenofovir disoproxil fumarate in children and adolescents are under investigation.
Farmakokinetikken af robenacoxib er ikke forskellig hos han- og hunhunde og er lineær i intervallet 0,5-8 mg/kg.
The pharmacokinetics of robenacoxib do not differ between male and female dogs, and are linear over the range 0.5–8 mg/kg.
Farmakokinetikken af robenacoxib-injektion er ikke forskellig hos henholdsvis han- og hunkatte og han- og hunhunde og er lineær i intervallet 0,25-4 mg/kg hos hunde.
The pharmacokinetics of robenacoxib injection do not differ between male and female cats and dogs, and are linear over the range of 0.25–4 mg/kg in dogs.
Farmakokinetikken af selexipag og den aktive metabolit hos PAH- patienter blev ikke påvirket af sygdommens sværhedsgrad og ændrede sig ikke over tid.
The pharmacokinetics of selexipag and the active metabolite in PAH patients were not influenced by the severity of the disease and did not change with time.
Farmakokinetikken af sunitinib blev vurderet hos 135 raske forsøgspersoner og 266 patienter med solide tumorer.
The pharmacokinetics of sunitinib were evaluated in 135 healthy volunteers and 266 patients with solid tumours.
Farmakokinetikken af vandetanib ved en dosis på 300 mg hos MTC-patienter er karakteriseret ved en clearance på ca.13,2 l/t og en plasmahalveringstid på ca.19 dage.
The pharmacokinetics of vandetanib at the 300 mg dose in MTC patients are characterised by a clearance of approximately 13.2 l/h. and plasma half-life of approximately 19 days.
Farmakokinetikken af Viraferon blev undersøgt hos raske forsøgspersoner efter enkeltdoser på 5 millioner IE/m2 og 10 millioner IE indgivet subkutant, ved doser på 5 millioner IE/m2 indgivet intramuskulært og som en 30 minutters intravenøs infusion.
The pharmacokinetics of Viraferon were studied in healthy volunteers following single 5 million IU/m2 and 10 million IU doses administered subcutaneously, at 5 million IU/m2 administered intramuscularly and as a 30-minute intravenous infusion.
Farmakokinetikken af Voncento blev evalueret hos hæmofili A-patienter, mens der ikke forekom blødninger.
The pharmacokinetics of Voncento have been evaluated in haemophilia A patients in the non-bleeding state.
Farmakokinetikken af Voncento blev evalueret hos patienter med von Willebrands sygdom, mens der ikke forekom blødninger.
The pharmacokinetics of Voncento have been evaluated in VWD patients in the non-bleeding state.
Farmakokinetikken bestemt med hensyn til populationer hos patienter med erektil dysfunktion er den samme som farmakokinetikken hos raske forsøgspersoner.
Pharmacokinetics determined with a population approach in patients with erectile dysfunction is similar to pharmacokinetics in subjects without erectile dysfunction.
Farmakokinetikken er blevet undersøgt hos pædiatriske patienter i 4 kliniske studier (BREATHE-3, FUTURE 1, FUTURE-3 OG FUTURE-4, se pkt.
Pharmacokinetics were studied in paediatric patients in 4 clinical studies (BREATHE-3, FUTURE 1, FUTURE-3 and FUTURE-4 see section 5.1).
Farmakokinetikken er ikke-lineær med øgning af arealet under plasmakoncentrationskurven (AUC) vs. tidskurven på 3,8 gange, når dosis fordobles fra 4,5 g til 9 g.
Pharmacokinetics is nonlinear with the area under the plasma concentration curve (AUC) versus time curve increasing 3.8-fold as dose is doubled from 4.5 g to 9 g.
Farmakokinetikken for 5-ALA hos patienter med nedsat nyre- eller leverfunktion er ikke undersøgt.
Pharmacokinetics of 5-ALA in patients with renal or liver impairment has not been investigated.
Farmakokinetikken for asfotase alfa blev evalueret i et 1-måneds, åbent, dosiseskalerende multicenterstudie hos voksne med hypophosphatasi.
Pharmacokinetics of asfotase alfa were evaluated in a 1-month, multicenter, open-label, dose- escalating, study in adults with hypophosphatasia.
Farmakokinetikken for brinzolamid er grundlæggende non-lineær på grund af den mættede binding til karboanhydrase i helblod og forskelligt væv.
Brinzolamide pharmacokinetics are inherently non-linear due to saturable binding to carbonic anhydrase in whole blood and various tissues.
Farmakokinetikken for ceftarolin var ens for mænd og kvinder.
The pharmacokinetics of ceftaroline was similar between males and females.
Farmakokinetikken for darunavir i kombination med ritonavir taget en gang dagligt hos
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in
Farmakokinetikken for dronedaron og dets N- debutylmetabolit afviger begge moderat fra dosisproportionalitet: En fordobling af dosis resulterer i en stigning på ca.
The pharmacokinetics of dronedarone and its N-debutyl metabolite both deviate moderately from dose proportionality: a 2-fold increase in dose results in an approximate 2.5- to
Farmakokinetikken for evolocumab blev påvirket af legemsvægt, uden at det havde nogen mærkbar virkning på sænkning af LDL-C.
The pharmacokinetics of evolocumab were influenced by body weight without having any notable effect on LDL-C lowering.
Farmakokinetikken for Fabrazyme blev også evalueret hos 15 pædiatriske patienter (8,5 til 16 år med en vægt mellem 27,1 og 64,9 kg).
Fabrazyme pharmacokinetics was also evaluated in 15 paediatric patients (8.5 to 16 years old weighing 27.1 to 64.9 kg).
Farmakokinetikken for flutemetamol (18F) hos patienter med nedsat nyre-eller leverfunktion er ikke beskrevet.
The pharmacokinetics of flutemetamol (18F) in patients with renal or hepatic impairment has not been characterised.
Farmakokinetikken for fondaparinuxnatrium skyldes fondaparinux plasmakoncentration, der kvantificeres gennem aktiviteten af anti faktor Xa.
The pharmacokinetics of fondaparinux sodium are derived from fondaparinux plasma concentrations quantified via anti factor Xa activity.
Farmakokinetikken for fulvestrant er blevet undersøgt i et klinisk enkeltdosis-studie, der blev gennemført hos forsøgspersoner som havde let til moderat nedsat leverfunktion, (Child-Pugh klasse A og B).
The pharmacokinetics of fulvestrant has been evaluated in a single-dose clinical trial conducted in subjects with mild to moderate hepatic impairment (Child-Pugh class A and B).
Farmakokinetikken for infliximab hos æ ldre patienter er ikke blevet undersøgt.
The pharmacokinetics of infliximab in elderly patients has not been studied.
Farmakokinetikken for intravenøst busulfan blev undersøgt hos 124 evaluerbare patienter efter 2 timers intravenøs infusion af i alt 16 doser i løbet af 4 dage.
The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2- hour intravenous infusion for a total of 16 doses over four days.
Farmakokinetikken for kombinationen af ombitasvir 25 mg, paritaprevir 200 mg og ritonavir 100 mg blev ikke undersøgt hos patienter med let nedsat leverfunktion (Child-Pugh A), moderat nedsat leverfunktion (Child-Pugh B) og svært nedsat leverfunktion (Child-Pugh C).
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg were not evaluated in subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child- Pugh C) hepatic impairment.
Farmakokinetikken for levofloxacin efter inhalation af Quinsair 240 mg to gange dagligt er blevet undersøgt for pædiatriske patienter med CF i alderen 12 år og derover, som vejede ≥ 30 kg.
The pharmacokinetics of levofloxacin following inhalation of Quinsair 240 mg twice daily were investigated in paediatric patients with CF aged 12 years and older and weighing ≥ 30 kg.
Farmakokinetikken for lurasidon hos pædiatriske patienter i aldersgruppen 6-17 år var generelt sammenlignelig med observationer hos voksne.
The pharmacokinetics of lurasidone in paediatric patients aged 6–17 years was generally comparable to those observed in adults.
Farmakokinetikken for lægemidler, der især metaboliseres af UGT1A3 og UGT1A9 kan blive påvirket, når det administreres samtidigt med ospemifen, og co-administrering bør foretages med forsigtighed.
The pharmacokinetics of drugs that are mainly metabolised by UGT1A3 and UGT1A9 could be affected when administered concomitantly with ospemifene and co-administration should be made with caution.
Farmakokinetikken for MabCampath fulgte en 2- kompartmentmodel og udviste non-lineær eliminationskinetik.
MabCampath pharmacokinetics followed a 2-compartment model and displayed non-linear elimination kinetics.
Farmakokinetikken for natriumoxybat i patienter yngre end 18 år er ikke undersøgt
The pharmacokinetics of sodium oxybate in paediatric patients under the age of 18 years have not been studied.
Farmakokinetikken for parathyreoideahormonet er ikke undersøgt hos patienter med svært nedsat nyrefunktion (kreatininclearance < 30 ml/min).
The pharmacokinetics of parathyroid hormone in patients with severe renal impairment (creatinine clearance of less than 30 mlmin) has not been investigated.
Farmakokinetikken for patienter med nedsat nyre- eller leverfunktion er ikke beskrevet.
The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Farmakokinetikken for posaconazol er sammenlignelig hos mænd og kvinder.
The pharmacokinetics of posaconazole are comparable in men and women.
Farmakokinetikken for posaconazol tabletter er sammenlignelig hos mænd og kvinder.
The pharmacokinetics of posaconazole tablets are comparable in men and women.
Farmakokinetikken for ribavirin og interferon alfa-2b (dosis-normaliseret) er ens hos voksne og børn eller unge.
The pharmacokinetics of ribavirin and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.
Farmakokinetikken for rimonabant er forholdsvis proportional op til 20 mg.
Rimonabant pharmacokinetics are fairly dose proportional up to about 20 mg.
Farmakokinetikken for riociguat er lineær fra 0,5 til 2,5 mg.
Riociguat pharmacokinetics are linear from 0.5 to 2.5 mg.
Farmakokinetikken for strontium og ranelinsyre er vurderet hos raske unge mænd og raske postmenopausale kvinder samt under langvarig eksponering af mænd med osteoporose og postmenopausale kvinder med osteoporose, herunder også ældre.
The pharmacokinetics of strontium and ranelic acid have been assessed in healthy young men and healthy postmenopausal women, as well as during long- term exposure in men with osteoporosis and postmenopausal osteoporotic women including elderly women.
Farmakokinetikken for TMZ var sammenlignelig for patienter med normal leverfunktion og patienter med let til moderat leverinsufficiens.
The pharmacokinetics of TMZ were comparable in patients with normal hepatic function and in those with mild or moderate hepatic impairment.
Farmakokinetikken for topotecan var generelt uændret, når det blev givet sammen med ranitidin.
The pharmacokinetics of topotecan was generally unchanged when coadministered with ranitidine.
Farmakokinetikken for total-irinotecan og total-SN-38 i plasma blev evalueret hos cancerpatienter, som fik ONIVYDE som enkeltstof eller som del af kombinationskemoterapi i doser på 60-180 mg/m².
The plasma pharmacokinetics of total irinotecan and total SN-38 were evaluated in patients with cancer who received ONIVYDE, as a single agent or as part of combination chemotherapy, at doses between 60 and 180 mg/m2.
Farmakokinetikken hos patienter med nyre- eller leverinsufficiens er ikke undersøgt.
The pharmacokinetics in patients with renal or hepatic impairment has not been characterised.
Farmakokinetikken hos patienter med nyre- eller leversygdomme er ikke beskrevet.
The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Farmakokinetikken hos patienter mellem 2 og 19 år med recidiverende eller refraktær ALL eller AML efter administration af gentagne doser clofarabin som intravenøs infusion
Pharmacokinetics in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML following administration of multiple doses of clofarabine by intravenous infusion
Farmakokinetikken hos patienter under 18 år er ikke blevet undersøgt.
The pharmacokinetics in patients below the age of 18 has not been studied.
Farmakokinetikken hos ældre ( 65 år) er ikke systematisk undersøgt.
Pharmacokinetic behaviour of CellCept in the elderly ( 65 years) has not been formally evaluated.
Farmakokinetikken hos ældre ( 65 år) er ikke systematisk undersøgt.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly ( 65 years) has not been formally evaluated.